Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases

1. A IFNgR2 binding molecule that specifically binds to the extracellular domain of IFNgR2, wherein the IFNgR2 binding molecule comprises a single domain antibody (sdAb).

2. The IFNgR2 binding molecule of claim 1 , wherein the sdAb comprises a complementary determining region 1 (CDR1), a CDR2, and a CDR3 as shown in a row of the table below:

CDR1

CDR2

CDR3

RTFTSYAMN

AISWSSGNTYVADSVKG

TTIATMSDEYTY

(SEQ ID NO: 34)

(SEQ ID NO: 35)

(SEQ ID NO: 36)

RTFSNYRMG

AISRGGGTTLYADSVKG

GDFSTTWDEYNY

(SEQ ID NO: 37)

(SEQ ID NO: 38)

(SEQ ID NO: 39)

RTFSSYAMG

AISRGGGSTDYADSVKG

RAYSGRYYQFLEYDY

(SEQ ID NO: 40)

(SEQ ID NO: 41)

(SEQ ID NO: 42)

RTFSSYAVA

ALSRGGGSAYYTDSVKG

RNYDGTYYQENQYNY

(SEQ ID NO: 43)

(SEQ ID NO : 44)

(SEQ ID NO: 45)

RTFSTYAMG

AISVNGGSTYYADSVTG

RRPYPGSDFLTWASYDY

(SEQ ID NO: 46)

(SEQ ID NO: 47)

(SEQ ID NO: 48)

RTFSYTTIG

VISAGGGSRDYADALKG

RRNTDTYTTTGDYDY

(SEQ ID NO: 49)

(SEQ ID NO: 50)

(SEQ ID NO: 51)

GTISSLAMG

AISWSGRSTYYVDSVKG

GEDGHSEYDY

(SEQ ID NO: 52)

(SEQ ID NO: 53)

(SEQ ID NO: 54)

RSFANYAMG

AISRGGGSTWYADSVKG

RSYSGSYTYSFGEYDY

(SEQ ID NO: 55)

(SEQ ID NO: 56)

(SEQ ID NO: 57)

RAFSTYALG

AISRGGGSTDYADSVKG

RSYSSSYYYSQYEYDY

(SEQ ID NO: 58)

(SEQ ID NO: 59)

(SEQ ID NO: 60)

RTFSSVAMA

AISSGGGSTDYADSVKG

RDYSSRRYYQSRYEYDL

(SEQ ID NO: 61)

(SEQ ID NO : 62)

(SEQ ID NO: 63)

RTFRSYSMG

AISWYSGTTYYADPVKG

NEIATMESSNDY

(SEQ ID NO: 64)

(SEQ ID NO: 65)

(SEQ ID NO: 66)

RPRTTYAMG

AISKAGGSTYVADSAKG

RAGFAAQIFEYDY

(SEQ ID NO: 67)

(SEQ ID NO: 68)

(SEQ ID NO: 69)

RTFGTYAMG

SIDRDGSMSYYADSVKG

SRRAVISLQTVDY

(SEQ ID NO: 70)

(SEQ ID NO: 71)

(SEQ ID NO: 72)

RTFSNYAMG

AISWYSGNTYYADSVKG

NQIATMISVGDY

(SEQ ID NO: 73)

(SEQ ID NO: 74)

(SEQ ID NO: 75)

SIFRLNLMG

HVGTTGNTAYADSVKG

DRWGQFS

(SEQ ID NO: 76)

(SEQ ID NO: 77)

(SEQ ID NO: 78)

RTFTGYAMG

VITWSGATTYYSASVKG

RIRDGVSPENPNEYGY

(SEQ ID NO: 79)

(SEQ ID NO: 80)

(SEQ ID NO: 81)

RTVGYGMA

AITWSGTSTYYPDSVKG

GSRRRVGVDVGGYDY

(SEQ ID NO: 82)

(SEQ ID NO: 83)

(SEQ ID NO: 84)

RTFTFSTHNMG

GIMWTSRASYADSVKG

AWYGNSGASYDY

(SEQ ID NO: 85)

(SEQ ID NO : 86)

(SEQ ID NO: 87)

RTFSGYNMG

AIAWAGSRTYYTDSVKG

HDETYYRLDRVDLYTH

(SEQ ID NO: 88)

(SEQ ID NO: 89)

(SEQ ID NO: 90)

PFTRYAMG

AISWSSGNTYYVDSVKG

NEVATMSGPDDY

(SEQ ID NO: 91)

(SEQ ID NO: 92)

(SEQ ID NO: 93)

GSFGRYTMG

VISWSGTNTYYADSVKG

RETYYSHWDERMEYDY

(SEQ ID NO: 94)

(SEQ ID NO : 95)

(SEQ ID NO: 96)

SIDSSYYVS

AINWGDSRTAYADSVKG

RIGLGGPVVAAPTRYPY

(SEQ ID NO: 97)

(SEQ ID NO: 98)

(SEQ ID NO : 99)

SILRFNVMS

VITSGGSTNYADSVKG

DESGQYY

(SEQ ID NO: 100)

(SEQ ID NO : 101)

(SEQ ID NO: 102)

LTTSSAALA

TITSGGGSTYYADSVKG

RFYSTTYYYREHEYSD

(SEQ ID NO: 103)

(SEQ ID NO: 104)

(SEQ ID NO: 105)

RTFGTSFGSLSMG

AISRNIGRTYYADSVKD

TNSYDDLRRSYAYDY

(SEQ ID NO: 106)

(SEQ ID NO : 107)

(SEQ ID NO: 108)

RTFSSLAMA

AISRSGGSTDYADSVKG

RDYSTLQYYNEYEYSD

(SEQ ID NO: 109)

(SEQ ID NO: 110)

(SEQ ID NO : 111)

PTFSTYAMA

AITQSGRTTYYEDSVKG

RDLWSDSPDDWRIYSF

(SEQ ID NO: 112)

(SEQ ID NO: 113)

(SEQ ID NO : 114)

RTLHNFAMA

AISKGGGSADYADSVKG

NDLASYSDSSYTSTSRYDY

(SEQ ID NO: 115)

(SEQ ID NO : 116)

(SEQ ID NO : 117)

RTFSSYAMA

AISILGGSADYEDSVQG

RRPAPSDSYWSSTSYAY

(SEQ ID NO: 118)

(SEQ ID NO : 119)

(SEQ ID NO : 120)

RTFSSLAMA

ATTILGGSADYGDPVKG

RRPAPSDNYWSPASYAY

(SEQ ID NO: 121)

(SEQ ID NO: 122)

(SEQ ID NO : 123)

RTFSSYAMA

AITVSGASTYYADSVKG

GGPGTIFPDYDY

(SEQ ID NO: 124)

(SEQ ID NO: 125)

(SEQ ID NO : 126)

RTFSGYNMG

AINWIGGATYYADSVKG

YSEKFYSGKDYYTRDYDY

(SEQ ID NO: 127)

(SEQ ID NO : 128)

(SEQ ID NO: 129).

3. The IFNgR2 binding molecule of claim 1 , wherein the sdAb has at least 95% identity to a polypeptide sequence of any one of SEQ ID NOS: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33.

4. The IFNgR2 binding molecule of claim 2 , wherein the sdAb is humanized or otherwise comprises CDRs grafted onto a heterologous framework.

5. The IFNgR2 binding molecule of claim 1 , further comprising a labeling agent, an imaging agent, and/or a therapeutic agent.

6. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:34, 35, and 36, respectively.

7. The IFNGR2 binding molecule of claim 6 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:2.

8. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:37, 38, and 39, respectively.

9. The IFNGR2 binding molecule of claim 8 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:3.

10. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:40, 41, and 42, respectively.

11. The IFNGR2 binding molecule of claim 10 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:4.

12. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:43, 44, and 45, respectively.

13. The IFNGR2 binding molecule of claim 12 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:5.

14. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:46, 47, and 48, respectively.

15. The IFNGR2 binding molecule of claim 14 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:6.

16. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:49, 50, and 51, respectively.

17. The IFNGR2 binding molecule of claim 16 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:7.

18. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:52, 53, and 54, respectively.

19. The IFNGR2 binding molecule of claim 18 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:8.

20. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:55, 56, and 57, respectively.

21. The IFNGR2 binding molecule of claim 20 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:9.

22. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:58, 59, and 60, respectively.

23. The IFNGR2 binding molecule of claim 22 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:10.

24. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:61, 62, and 63, respectively.

25. The IFNGR2 binding molecule of claim 24 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:11.

26. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:64, 65, and 66, respectively.

27. The IFNGR2 binding molecule of claim 26 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:12.

28. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:67, 68, and 69, respectively.

29. The IFNGR2 binding molecule of claim 28 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:13.

30. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:70, 71, and 72, respectively.

31. The IFNGR2 binding molecule of claim 30 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:14.

32. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:73, 74, and 75, respectively.

33. The IFNGR2 binding molecule of claim 32 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:15.

34. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:76, 77, and 78, respectively.

35. The IFNGR2 binding molecule of claim 34 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:16.

36. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:79, 80, and 81, respectively.

37. The IFNGR2 binding molecule of claim 36 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:17.

38. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:82, 83, and 84, respectively.

39. The IFNGR2 binding molecule of claim 38 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:18.

40. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:85, 86, and 87, respectively.

41. The IFNGR2 binding molecule of claim 40 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:19.

42. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:88, 89, and 90, respectively.

43. The IFNGR2 binding molecule of claim 42 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:20.

44. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:91, 92, and 93, respectively.

45. The IFNGR2 binding molecule of claim 44 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:21.

46. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:94, 95, and 96, respectively.

47. The IFNGR2 binding molecule of claim 46 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:22.

48. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:97, 98, and 99, respectively.

49. The IFNGR2 binding molecule of claim 48 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:23.

50. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:100, 101, and 102, respectively.

51. The IFNGR2 binding molecule of claim 50 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:24.

52. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:103, 104, and 105, respectively.

53. The IFNGR2 binding molecule of claim 52 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:25.

54. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:106, 107, and 108, respectively.

55. The IFNGR2 binding molecule of claim 54 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:26.

56. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:109, 110, and 111, respectively.

57. The IFNGR2 binding molecule of claim 56 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:27.

58. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:112, 113, and 114, respectively.

59. The IFNGR2 binding molecule of claim 58 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:28.

60. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:115, 116, and 117, respectively.

61. The IFNGR2 binding molecule of claim 60 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:29.

62. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:118, 119, and 120, respectively.

63. The IFNGR2 binding molecule of claim 62 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:30.

64. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:121, 122, and 123, respectively.

65. The IFNGR2 binding molecule of claim 64 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:31.

66. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:124, 125, and 126, respectively.

67. The IFNGR2 binding molecule of claim 66 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:32.

68. The IFNGR2 binding molecule of claim 1 , wherein the sdAb comprises the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:127, 128, and 129, respectively.

69. The IFNGR2 binding molecule of claim 68 , wherein the sdAb has at least 95% identity to a polypeptide sequence of SEQ ID NO:33.

70. The IL2Rg2 binding molecule of claim 1 , wherein the sdAb is linked to a second binding molecule that specifically binds to the extracellular domain of a second cell surface molecule.

71. A pharmaceutically acceptable formulation of an IFNgR2 binding molecule of claim 2 .

72. A kit comprising the IFNgR2 binding molecule of claim 1 .

73. A nucleic acid encoding the sequence of the IL2Rg2 binding molecule of claim 1 .

74. The nucleic acid sequence of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:34, 35, and 36, respectively.

75. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:37, 38, and 39, respectively.

76. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:40, 41, and 42, respectively.

77. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:43, 44, and 45, respectively.

78. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:46, 47, and 48, respectively.

79. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:49, 50, and 51, respectively.

80. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:52, 53, and 54, respectively.

81. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:55, 56, and 57, respectively.

82. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:58, 59, and 60, respectively.

83. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:61, 62, and 63, respectively.

84. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:64, 65, and 66, respectively.

85. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:67, 68, and 69, respectively.

86. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:70, 71, and 72, respectively.

87. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:73, 74, and 75, respectively.

88. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:76, 77, and 78, respectively.

89. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:79, 80, and 81, respectively.

90. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:82, 83, and 84, respectively.

91. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:85, 86, and 87, respectively.

92. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:88, 89, and 90, respectively.

93. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:91, 92, and 93, respectively.

94. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:94, 95, and 96, respectively.

95. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:97, 98, and 99, respectively.

96. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:100, 101, and 102, respectively.

97. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:103, 104, and 105, respectively.

98. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:106, 107, and 108, respectively.

99. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:109, 110, and 111, respectively.

100. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:112, 113, and 114, respectively.

101. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:115, 116, and 117, respectively.

102. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:118, 119, and 120, respectively.

103. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:121, 122, and 123, respectively.

104. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:124, 125, and 126, respectively.

105. The nucleic acid of claim 73 , encoding the sequence of the IL2Rg2 binding molecule comprising the sdAb having the CDR1, the CDR2, and the CDR3 of SEQ ID NOS:127, 128, and 129, respectively.

106. A recombinant viral or non-viral vector comprising the nucleic acid of claim 73 .

107. A host cell comprising the nucleic acid of claim 73 .

108. A method for treating an autoimmune or inflammatory disease, disorder, or condition in a mammalian subject by administering to said subject a therapeutically effective amount of a IFNgR2 binding molecule of claim 1 .

109. A pharmaceutical formulation comprising the viral or non-viral vector of claim 106 .